Northwire Canada EditionSaturday, July 18, 2026
Sign inSubscribe
Northwire
⌕
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%
Financings

Quantum Biopharma licensee Unbuzzd to host webinar

By The Northwire Desk — AI Analysis Oct 23, 2025 · 18:28 QNTM · 19.80 Quantum Biopharma Ltd
QNTM · Price

Executive Summary

  • Quantum Biopharma Ltd.'s licensee, Unbuzzd Wellness Inc., is hosting a live investor webinar on October 30, 2025, to discuss its Regulation D 506(c) offering targeting up to $5 million in U.S. capital.
  • The offering is strictly for accredited investors, and Quantum Biopharma shareholders will not be diluted by this specific capital raise.
  • Quantum Biopharma retains a 20.10% equity stake in Unbuzzd Wellness (as of June 30, 2025) and is entitled to a 7% royalty on sales until $250 million is reached, after which it drops to 3% in perpetuity.

Key Details

  • Webinar Details: Hosted by Unbuzzd Wellness Inc. on Thursday, Oct. 30, 2025, at 4:15 p.m. EST (1:15 p.m. PST).
  • Financing Structure: Regulation D 506(c) offering.
  • Capital Raise Target: Up to $5 million (U.S.).
  • Use of Proceeds: Expand direct-to-consumer, distributor, and retail channel availability; work toward a possible IPO.
  • Dilution Impact: Explicitly stated that Quantum Biopharma shareholders will not be diluted by this offering.
  • Investor Eligibility: Accredited investors only.
  • Equity Stake: Quantum Biopharma owns 20.10% of Unbuzzd Wellness (as of June 30, 2025).
  • Royalty Agreement: Quantum Biopharma receives 7% of Unbuzzd sales until cumulative payments reach $250 million; thereafter, the royalty rate drops to 3% in perpetuity.
  • IP Rights: Quantum Biopharma retains 100% of rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
  • Key Speakers: John Duffy (CEO, Unbuzzd), Jason Sawyer (Adviser), Dr. Eric Hoskins (Medical Director), Gerry David (Board Co-Chair, former CEO of Celsius).

Notable Quotes

  • John Duffy, CEO of Unbuzzd: "We invite potential investors to discuss our Regulation D 506(c) offering, targeting $5.0-million (U.S.) to expand unbuzzd direct-to-consumer, distributor and retail channel availability and work toward a possible IPO. Unbuzzd has the potential to be one of the most impactful new products of 2026 due to the meaningful innovation, functionality, relevance and backing by clinical research."
Read the original news release →

More from Quantum Biopharma Ltd

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other